Literature DB >> 21883670

Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates.

G A Tramper-Stranders1, C K van der Ent, S Molin, L Yang, S K Hansen, M H Rau, O Ciofu, H K Johansen, T F W Wolfs.   

Abstract

Despite intensive eradication therapy, some CF patients with early Pseudomonas aeruginosa infection rapidly develop a chronic infection. To elucidate factors associated with this persistence, bacterial characteristics of early P. aeruginosa isolates were analysed that were either eradicated rapidly or persisted despite multiple antimicrobial treatments. Eighty-six early infection episodes were studied. First P. aeruginosa isolates from patients with eradication (36) or persistent infection (16) were included; isolates from patients with intermittent infection (34) were omitted from the study. Virulence assays, antimicrobial resistance, cytotoxicity and mutation frequencies were analysed in vitro. P. aeruginosa was genotyped by SNP-array. Transcriptomic profiles of two eradicated and two persistent strains were compared. Nineteen per cent of patients developed persistent infection; 42% achieved eradication. Secretion of virulence factors and mutation frequencies were highly variable among both eradicated and persistent isolates and were not different between the groups. Cytotoxicity was present in 57% of eradicated vs. 100% of persistent isolates (p <0.01). None of the isolates were resistant to antibiotics. The isolates were genotypically highly diverse. Multivariate analysis showed that in vitro determined bacterial characteristics could not predict persistence after first P. aeruginosa infection. Preliminary transcriptomic data showed increased expression of some genes related to a metabolic pathway. The early onset of chronic infection was not associated with (in vitro determined) bacterial characteristics only. Although the persistent isolates were more often cytotoxic, for the individual patient it was not possible to predict the risk of persistence based on bacterial characteristics. Unknown factors such as host-pathogen and pathogen-pathogen interactions should be further explored.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883670     DOI: 10.1111/j.1469-0691.2011.03627.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  20 in total

1.  Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Hemantha D Kulasekara; Daniel J Wolter; Laura S Houston; Christopher E Pope; Bridget R Kulasekara; Catherine R Armbruster; Jane L Burns; George Retsch-Bogart; Margaret Rosenfeld; Ronald L Gibson; Samuel I Miller; Umer Khan; Lucas R Hoffman
Journal:  Clin Infect Dis       Date:  2014-05-26       Impact factor: 9.079

Review 2.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

3.  [Cystic fibrosis and associated complications].

Authors:  C Schwarz; D Staab
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

4.  Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in Pseudomonas aeruginosa.

Authors:  Patrick R Secor; Lia A Michaels; Anina Ratjen; Laura K Jennings; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

5.  Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection.

Authors:  Benjamin J Staudinger; Jocelyn Fraga Muller; Skarphéðinn Halldórsson; Blaise Boles; Angus Angermeyer; Dao Nguyen; Henry Rosen; Olafur Baldursson; Magnús Gottfreðsson; Guðmundur Hrafn Guðmundsson; Pradeep K Singh
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

6.  Population structure and antimicrobial susceptibility of both nonpersistent and persistent Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.

Authors:  Ana Fernández-Olmos; María García-Castillo; José María Alba; María Isabel Morosini; Adelaida Lamas; Beatriz Romero; Juan Carlos Galán; Rosa del Campo; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

7.  Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.

Authors:  P Vidya; L Smith; T Beaudoin; Y C Yau; S Clark; B Coburn; D S Guttman; D M Hwang; V Waters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01       Impact factor: 3.267

8.  Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium.

Authors:  Iwona Bucior; Julia F Pielage; Joanne N Engel
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

9.  The extracellular matrix Component Psl provides fast-acting antibiotic defense in Pseudomonas aeruginosa biofilms.

Authors:  Nicole Billings; MariaRamirez Millan; Marina Caldara; Roberto Rusconi; Yekaterina Tarasova; Roman Stocker; Katharina Ribbeck
Journal:  PLoS Pathog       Date:  2013-08-08       Impact factor: 6.823

Review 10.  Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  Matthew N Hurley; Miguel Cámara; Alan R Smyth
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.